EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Method of Minimal Residual Disease Detection With Circulating Tumor DNA and Its Clinical Applications in Colorectal Cancer

Ming Liu iD, Tianhao Mu, Jia Gu, Mingyan Xu, Shifu Chen

Cancer Reports · 2025

DOI: 10.1002/cnr2.70167 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Reports, 2025. Verfasst von Ming Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: HaploX Biotechnology, Shenzhen, China. Hauptthemen laut MEDLINE: Neoplasm, Residual, Circulating Tumor DNA, Colorectal Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Province Key Areas R&D Plan Project Fund, Shenzhen Science and Technology Innovation Committee Technical Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colorectal cancer (CRC) remains a significant health concern in the world. The existing standard of care guidelines for CRC surveillance fall short of effectively and timely detecting recurrence or metastasis. Recent Findings In recent years, circulating tumor DNA (ctDNA) has emerged as a promising material for minimal residual disease (MRD) detection. In this article, we provide an exhaustive review of the methods utilized for MRD detection via ctDNA, present evidence supporting the potential of ctDNA MRD as a valuable biomarker in clinical applications, and engage in a discussion regarding ongoing ctDNA MRD‐based clinical trials in CRC. Finally, we offer insights into future prospects of ctDNA‐based MRD methodological advancements and clinical research.

Conclusion

It is foreseeable that more sensitive, flexible, and economical MRD detection methods will emerge with the deeper research on cell‐free DNA (cfDNA) genomics, fragmentomics, methylomes, and nucleosome imprinting. At the same time, MRD‐guided intervention studies will evolve for revolutionizing the treatment paradigm of CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualCirculating Tumor DNAColorectal NeoplasmsBiomarkers, TumorNeoplasm Recurrence, LocalHumans

Stichwörter der Autor:innen

circulating tumor DNAclinical applicationsclinical trialscolorectal cancerminimal residual disease

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • HaploX Biotechnology, Shenzhen, China.
  • Faculty of Data Science, City University of Macau, Macau, China.

ORCID-Profile: Ming Liu

Förderung

  • Guangdong Province Key Areas R&D Plan Project Fund
  • Shenzhen Science and Technology Innovation Committee Technical Research Project

Zitieren

APA

Liu, M., Mu, T., Gu, J., Xu, M., & Chen, S. (2025). The Method of Minimal Residual Disease Detection With Circulating Tumor DNA and Its Clinical Applications in Colorectal Cancer. Cancer Reports. https://doi.org/10.1002/cnr2.70167

Vancouver

Liu M, Mu T, Gu J, Xu M, Chen S. The Method of Minimal Residual Disease Detection With Circulating Tumor DNA and Its Clinical Applications in Colorectal Cancer. Cancer Reports. 2025. doi:10.1002/cnr2.70167

BibTeX
@article{Liu2025,
  author = {Liu, Ming and Mu, Tianhao and Gu, Jia and Xu, Mingyan and Chen, Shifu},
  title = {The Method of Minimal Residual Disease Detection With Circulating Tumor DNA and Its Clinical Applications in Colorectal Cancer},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70167}
}
Kostenlos starten →